ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,139.33
-0.30%
Dow Jones
38,367.16
-0.72%
Gold vs US Dollar
2,329.745
1.18%
Brent Oil
82.575
0.73%
Bitcoin
66,856.53
0.17%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NRX Pharmaceuticals Inc (NRXP)

  7. NRX Pharmaceuticals Inc (NRXP) News

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRXP
DateTimeSourceHeadlineSymbolCompany
10/06/202413:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update LetterNASDAQ:NRXPNRX Pharmaceuticals Inc
28/05/202413:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in BipolaNASDAQ:NRXPNRX Pharmaceuticals Inc
14/05/202421:01PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
08/05/202413:30PR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
07/05/202421:01PR Newswire (US)NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
06/05/202413:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
30/04/202413:30PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
18/04/202413:32PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementNASDAQ:NRXPNRX Pharmaceuticals Inc
18/04/202413:30PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
17/04/202421:45PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common StockNASDAQ:NRXPNRX Pharmaceuticals Inc
17/04/202413:30PR Newswire (US)NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsNASDAQ:NRXPNRX Pharmaceuticals Inc
15/04/202413:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
08/04/202413:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
01/04/202413:28PR Newswire (US)NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NRXPNRX Pharmaceuticals Inc
28/03/202412:03PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End HighlightsNASDAQ:NRXPNRX Pharmaceuticals Inc
28/03/202412:00PR Newswire (US)NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:NRXPNRX Pharmaceuticals Inc
26/03/202420:03PR Newswire (US)UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
25/03/202412:30PR Newswire (US)NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKNASDAQ:NRXPNRX Pharmaceuticals Inc
21/03/202420:02PR Newswire (US)NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024NASDAQ:NRXPNRX Pharmaceuticals Inc
21/03/202417:57PR Newswire (US)NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersNASDAQ:NRXPNRX Pharmaceuticals Inc
12/03/202411:49PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short SalesNASDAQ:NRXPNRX Pharmaceuticals Inc
11/03/202421:16Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NRXPNRX Pharmaceuticals Inc
11/03/202412:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)NASDAQ:NRXPNRX Pharmaceuticals Inc
06/03/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRXPNRX Pharmaceuticals Inc
04/03/202413:30PR Newswire (US)NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionNASDAQ:NRXPNRX Pharmaceuticals Inc
01/03/202413:30PR Newswire (US)NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per ShareNASDAQ:NRXPNRX Pharmaceuticals Inc
28/02/202422:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRXPNRX Pharmaceuticals Inc
28/02/202415:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRXPNRX Pharmaceuticals Inc
27/02/202415:49PR Newswire (US)/C O R R E C T I O N -- NRx Pharmaceuticals, Inc./NASDAQ:NRXPNRX Pharmaceuticals Inc
27/02/202413:54PR Newswire (US)NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 millionNASDAQ:NRXPNRX Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NRXP

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
GKP
Gulf Keystone Petroleum
LSE
TERN
Tern
LSE
SCLP
Scancell
LSE
POS
Plexus
LSE
HE1
Helium One Global
LSE
THG
Thg
LSE
GGP
Greatland Gold
LSE
SQZ
Serica Energy
LSE
BIRD
Blackbird
LSE
RPI
Raspberry Pi
LSE
VAST
Vast Resources
LSE
EEE
Empire Metals
LSE
BOO
Boohoo
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved